nb124

ELX-02, also known as NB-124, is a eukaryotic ribosomal selective glycoside (ERSG) designed to increase the read-through activity in patients with nonsense mutations and enable the production of sufficient amounts of full-length functional protein to rest

ELX-02 disulfate (also referred to as NB-124 disulfate) is a synthetic eukaryotic ribosome selective glycoside (ERSG). This compound is currently in development as a therapy specifically designed to address genetic diseases resulting from nonsense mutations.

ELX-02 sulfate, also known as NB-124 sulfate, is a novel compound currently under development as a therapeutic agent for genetic diseases triggered by nonsense mutations. This investigational compound, an advanced synthetic eukaryotic ribosome selective glycoside (ERSG), shows promising potential for targeted treatment.